REGULATORY SUPPORT • Drug delivery devices • Pharmaceutical packaging • Medical equipment KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number level, reducing the risk of change • Allows crystallization in semi-crystalline polymers to begin faster and complete earlier REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request Healthcare use limitations apply—see below.

KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number level, reducing risk of change • Non-phthalate and formulated without animal-derived substances • Different tones of amber available on request —more or less red or yellow and/or lighter or darker • Also available in liquid form REGULATORY SUPPORT • Pre-tested raw materials: - ISO 10993-1 and USP parts (Class VI) - European Pharmacopeia, monograph 3.1.15, USP and elemental analysis as per ICH Q3D - USP criteria appearance of solution, color • Registered Drug Master File (Type III) by the FDA • Food contact compliance established with FDA/EU* • YBB00102002-2015 (oral liquid pharmaceutical PET bottles) compliance support APPLICATION BULLETIN * FDA/EU compliance information available upon request Healthcare use limitations apply—see below.

: 14/12/1990 Company Type : PRIVATE COMPANY LIMITED BY SHARES Status : Live Company Status Date : 14/12/1990 Principal Activities Activities (I) WHOLESALE TRADE OF A VARIETY OF GOODS WITHOUT A DOMINANT PRODUCT (46900) : IMPORT/EXPORT AND SALES OF POLYMERS Description : Activities (II) : Description Capital CurrencyIssued Share Capital Share TypeNumber of Shares * (AMOUNT) 694600 SINGAPORE, DOLLARS ORDINARY694600 7200000 UNITED STATES OF AMERICA, DOLLARS ORDINARY7200000 * Number of Shares includes number of Treasury Shares CurrencyPaid-Up Capital Share TypeNumber of Shares (AMOUNT) 694600 SINGAPORE, DOLLARS ORDINARY 7200000 UNITED STATES OF AMERICA, DOLLARS ORDINARY Page 1 of 4 Number Of Shares Currency COMPANY HAS THE FOLLOWING ORDINARY SHARES HELD AS TREASURY SHARES Registered Office Address 3 INTERNATIONAL BUSINESS PARK #04-14/15 NORDIC EUROPEAN CENTRE SINGAPORE (609927) Date of Address 16/08/2020: Date of Last AGM : 29/08/2020 Date of Last AR : 26/10/2020 FYE As At Date of Last AR : 31/12/2019 Audit Firms NAME ERNST & YOUNG LLP Amount Secured Chargee(s) Charges CurrencyCharge No.

These properties make TPEs useful in medical applications such as disposable gloves that serve as a guard against biohazards and pathogens without concern for latex allergies.

These properties make TPEs useful in medical applications such as disposable gloves that serve as a guard against biohazards and pathogens without concern for latex allergies.

Slide 1 PolyOne Corporation Page 1 PolyOne Investor Presentation Bank of America Merrill Lynch 2014 US Basic Materials Conference Boston, MA December 11, 2014 PolyOne Corporation Page 2 Forward-Looking Statements  In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You are advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission.

Slide 1 PolyOne Corporation Page 0 PolyOne Investor Presentation Jefferies 2014 Global Industrials Conference New York, NY August 12, 2014 PolyOne Corporation Page 1 Forward-Looking Statements  In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You are advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission.

Slide 1 PolyOne Corporation Page 1 PolyOne Investor Presentation Credit Suisse Basic Materials Conference June 25-26, 2014 PolyOne Corporation Page 2 Forward-Looking Statements  In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You are advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission.

PolyOne Corporation Investor Day 2012 PolyOne Investor Presentation Goldman Sachs Basic Materials Conference May 21, 2014 • In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You are advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission.

IR Deck - AVNT-2024.06.30 (Earnings) AVIENT CORPORATION S E C O N D Q U A R T E R 2 0 2 4 R E S U L T S A N D 2 0 2 4 F I N A N C I A L G U I D A N C E (NYSE: AVNT) AU G U S T 6 , 2 0 2 4 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You are advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission.